Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM-CSF + cytarabine + etoposide + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination chemotherapy regimen consisting of GM-CSF (granulocyte colony-stimulating factor), cytarabine, etoposide, and mitoxantrone. This regimen is primarily used for the treatment of relapsed or refractory acute myeloid leukemia (AML) and other high-grade myeloid neoplasms. GM-CSF stimulates bone marrow to produce white blood cells, while the three chemotherapeutic agents target rapidly dividing cancer cells through different mechanisms.
02
Targets
Beyond the preview
Go deeper on GM-CSF + cytarabine + etoposide + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM-CSF + cytarabine + etoposide + mitoxantrone.